← Product Code [QNP](/productcode/QNP) · K260567 # EW10-EC02 Endoscopy Support Program (K260567) _Fujifilm Corporation · QNP · Aug 7, 2026 · Gastroenterology, Urology · SESE_ **Canonical URL:** https://fda-staging.innolitics.com/device/K260567 ## Device Facts - **Applicant:** Fujifilm Corporation - **Product Code:** [QNP](/productcode/QNP.md) - **Decision Date:** Aug 7, 2026 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 876.1520 - **Device Class:** Class 2 - **Review Panel:** Gastroenterology, Urology - **Attributes:** AI/ML, Software as a Medical Device ## Indications for Use This software is a computer-assisted reading tool designed to aid endoscopists in detecting colonic mucosal lesions (such as polyps and adenomas) in real time during standard endoscopy examinations of patients undergoing screening and surveillance endoscopic mucosal evaluations. This software is used with standard WLI (White Light Imaging) and LCI (Linked Color Imaging) endoscopy imaging. This software is not intended to replace clinical decision making. ## Device Story Computer-assisted reading tool; aids endoscopists in real-time detection of colonic mucosal lesions (polyps/adenomas) during colonoscopy. Inputs: real-time video feed from endoscope using WLI or LCI imaging. Processing: AI-based CAD system analyzes video frames to identify suspected polyps. Output: visual assistance to the endoscopist during the procedure. Context: used in clinical settings by physicians; intended to support, not replace, clinical decision-making. Benefit: potential for increased polyp detection rates during screening and surveillance. ## Clinical Evidence Bench testing only. Standalone performance testing conducted using the same protocol as the predicate device. Performance assessed via object-level and frame-level analysis of >55 pre-recorded cases using the EP-8000 processor. Results demonstrated substantial equivalence to the predicate. ## Technological Characteristics AI-based CAD software for real-time endoscopic image analysis. Compatible with WLI and LCI imaging modes. Operates with specific Fujifilm processor (EP-8000) and endoscope systems. Software utilizes deep learning algorithms for lesion detection. ## Regulatory Identification A gastrointestinal lesion software detection system is a computer-assisted detection device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract. This device with advanced software algorithms brings attention to images to aid in the detection of lesions. The device may contain hardware to support interfacing with an endoscope. ## Special Controls In combination with the general controls of the FD&C Act, the gastrointestinal lesion software detection system is subject to the following special controls: *Classification.* Class II (special controls). The special controls for this device are:(1) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including detection of gastrointestinal lesions and evaluation of all adverse events. (2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Testing must include: (i) Standalone algorithm performance testing; (ii) Pixel-level comparison of degradation of image quality due to the device; (iii) Assessment of video delay due to marker annotation; and (iv) Assessment of real-time endoscopic video delay due to the device. (3) Usability assessment must demonstrate that the intended user(s) can safely and correctly use the device. (4) Performance data must demonstrate electromagnetic compatibility and electrical safety, mechanical safety, and thermal safety testing for any hardware components of the device. (5) Software verification, validation, and hazard analysis must be provided. Software description must include a detailed, technical description including the impact of any software and hardware on the device's functions, the associated capabilities and limitations of each part, the associated inputs and outputs, mapping of the software architecture, and a description of the video signal pipeline. (6) Labeling must include: (i) Instructions for use, including a detailed description of the device and compatibility information; (ii) Warnings to avoid overreliance on the device, that the device is not intended to be used for diagnosis or characterization of lesions, and that the device does not replace clinical decision making; (iii) A summary of the clinical performance testing conducted with the device, including detailed definitions of the study endpoints and statistical confidence intervals; and (iv) A summary of the standalone performance testing and associated statistical analysis. ## Predicate Devices - EW10-EC02 Endoscopy Support Program ([K230751](/device/K230751.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} ![LOGO](FDA U.S. FOOD & DRUG ADMINISTRATION) August 7, 2026 Fujifilm Corporation % Chaitrali Kulkarni Sr. Regulatory Affairs Specialist Fujifilm Healthcare Americas Corporation 81 Hartwell Ave. Suite 100 Lexington, Massachusetts 02421 Re: K260567 Trade/Device Name: EW10-EC02 Endoscopy Support Program Regulation Number: 21 CFR 876.1520 Regulation Name: Gastrointestinal Lesion Software Detection System Regulatory Class: Class II Product Code: QNP Dated: February 19, 2026 Received: February 19, 2026 Dear Chaitrali Kulkarni: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K260567 - Chaitrali Kulkarni Page 2 Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {2} K260567 - Chaitrali Kulkarni Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, SIVAKAMI VENKATACHALAM -S for Shanil P. Haugen, Ph.D. Assistant Director DHT3A: Division of Renal, Gastrointestinal, Obesity and Transplant Devices OHT3: Office of Gastrorenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K260567 | ? | | Please provide the device trade name(s). | | ? | | EW10-EC02 Endoscopy Support Program | | | | Please provide your Indications for Use below. | | ? | | This software is a computer-assisted reading tool designed to aid endoscopists in detecting colonic mucosal lesions (such as polyps and adenomas) in real time during standard endoscopy examinations of patients undergoing screening and surveillance endoscopic mucosal evaluations. This software is used with standard WLI (White Light Imaging) and LCI (Linked Color Imaging) endoscopy imaging. This software is not intended to replace clinical decision making. | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | {4} K260567 Page 1 of 2 510(k) #: K260567 # 510(k) Summary Prepared on: 2026-07-09 ## Contact Details 21 CFR 807.92(a)(1) Applicant Name FUJIFILM Corporation Applicant Address 798 Miyanodai Kaise-Machi Ashigarakami-Gun Kanagawa 258-8538 Japan Applicant Contact Telephone 704-517-4886 Applicant Contact Ms. Chaitrali Kulkarni Applicant Contact Email hcusregulatoryaffairs@fujifilm.com Correspondent Name Fujifilm Healthcare Americas Corporation Correspondent Address 81 Hartwell Ave. Suite 100 Lexington MA 02421 United States Correspondent Contact Telephone 704-517-4886 Correspondent Contact Ms. Chaitrali Kulkarni Correspondent Contact Email hcusregulatoryaffairs@fujifilm.com ## Device Name 21 CFR 807.92(a)(2) Device Trade Name EW10-EC02 Endoscopy Support Program Common Name Gastrointestinal lesion software detection system Classification Name Gastrointestinal Lesion Software Detection System Regulation Number 876.1520 Product Code(s) QNP ## Legally Marketed Predicate Devices 21 CFR 807.92(a)(3) Predicate # Predicate Trade Name (Primary Predicate is listed first) Product Code K230751 EW10-EC02 Endoscopy Support Program QNP ## Device Description Summary 21 CFR 807.92(a)(4) A. Intended Use/indications for Use This software is a computer-assisted reading tool designed to aid endoscopists in detecting colonic mucosal lesions (such as polyps and adenomas) in real time during standard endoscopy examinations of patients undergoing screening and surveillance endoscopic mucosal evaluations. This software is used with standard WLI (White Light Imaging) and LCI (Linked Color Imaging) endoscopy imaging. This software is not intended to replace clinical decision making. This software is not intended to replace clinical decision making. B. Device Description There is an increasing interest in the application of artificial intelligence (AI) in health care to improve disease diagnosis, management, and the development of effective therapies. The remarkable development of AI from deep learning in recent years has increased the {5} K260567 Page 2 of 2 possibility of machines assisting assessments by human visual observation. The subject device represents application of AI technology to endoscopic images to assist in detecting the presence of potential lesions. This development greatly contributes to improving the quality of colonoscopy. In recent years, computer-aided diagnosis (CAD) systems employing AI technologies have been approved and marketed as radiological medical devices for use with computed tomography (CT), X-ray, magnetic resonance imaging (MRI), and mammogram diagnostic images. In endoscopy as well, many images for diagnosis are taken. Since increasing the polyp detection rate is also in demand, CAD systems for endoscopy are being actively developed. Against this background, the company has developed this software (EW10-EC02), a new AI-based CAD system, to support Health Care Provider (HCP) detection of large intestine polyps in colonoscopic images. EW10-EC02 detects suspected large intestine polyps in the endoscope video image in real-time. ## Intended Use/Indications for Use 21 CFR 807.92(a)(5) This software is a computer-assisted reading tool designed to aid endoscopists in detecting colonic mucosal lesions (such as polyps and adenomas) in real time during standard endoscopy examinations of patients undergoing screening and surveillance endoscopic mucosal evaluations. This software is used with standard WLI (White Light Imaging) and LCI (Linked Color Imaging) endoscopy imaging. This software is not intended to replace clinical decision making. ## Indications for Use Comparison 21 CFR 807.92(a)(5) The indication for use for the proposed device and the predicate devices are same. ## Technological Comparison 21 CFR 807.92(a)(6) There is a difference in the compatible processor and endoscope between the subject device and the predicate device. Testing for the new compatible processor and endoscope was performed using the worst-case model specifications for the combination endoscope system, no new concerns for safety or efficacy was seen. ## Non-Clinical and/or Clinical Tests Summary & Conclusions 21 CFR 807.92(b) Verification and validation testing for the new compatible processor and endoscope was performed, no new concerns for safety or efficacy was seen. Standalone Performance Testing was conducted in accordance with the same evaluation protocol as that used for the predicate device to assess the performance of the subject device. The results from object-level and frame-level assessments of more than 55 pre-recorded cases with EP-8000 processor demonstrated substantial equivalence to the predicate device. --- **Source:** [https://fda-staging.innolitics.com/device/K260567](https://fda-staging.innolitics.com/device/K260567) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com